Condition

Hodgkin Lymphoma clinical trials and research

• 64Clinical trials
• 31NIH research projects
• 27Countries

Newest Hodgkin Lymphoma clinical trials

All recruiting trials (64)

• New ways to diagnose lymphoma and multicentric Castleman disease in people living with HIV

  This study tests a quick, point-of-care nucleic acid test to help diagnose lymphoma and multicentric Castleman disease in people living with HIV in sub-Saharan Africa.

  Recruiting Indiana University · Lilongwe · NCT07793006

• JLM019 Injection in Adults with Advanced Cancers

  This study tests JLM019 Injection in adults with advanced solid tumors or relapsed/refractory lymphomas to see if it’s safe and tolerable.

  Recruiting Phase 1 Jecho Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality · NCT07623850

• Cord blood transplant for children and young adults with blood cancers.

  This study will test whether a cord blood transplant given as a first or second transplant can help children and young adults with leukemia, myelodysplasia, or lymphoma who lack a matched donor.

  Recruiting Phase 2 Memorial Sloan Kettering Cancer Center · New York, New York · NCT07566377

• Nivolumab plus AVD for newly diagnosed early-stage non-bulky classical Hodgkin lymphoma in young patients

  This study tests whether nivolumab added to AVD can help children, teens, and young adults with newly diagnosed early-stage non-bulky Hodgkin lymphoma.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT07551583

• Adaptive Proton Therapy for Pediatric Solid Tumors and Hodgkin Lymphoma

  This study tests a regular imaging approach to see if proton therapy plans for children with solid tumors or Hodgkin lymphoma should be updated during treatment.

  Recruiting St. Jude Children's Research Hospital · Memphis, Tennessee · NCT07514819

• Autologous CD45 base-edited stem cells plus CART-45 cells for relapsed or refractory hematologic cancers

  This phase 1 study tests whether a patient’s own edited stem cells and CART-45 cells can be given safely to treat relapsed or refractory B-cell and T-cell lymphomas and Hodgkin lymphoma.

  Recruiting Phase 1 University of Pennsylvania · Philadelphia, Pennsylvania · NCT07451054

• CAR27/IL-15 NK cells with TGFBR2 KO for relapsed or refractory lymphoid cancers

  This phase 1 basket trial tests a modified natural killer cell therapy (CAR27/IL‑15 NK cells with TGFBR2 knocked out) in adults with relapsed or refractory B-cell lymphomas, Hodgkin lymphoma, T-cell lymphomas, or B-ALL after lymphodepletion.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT07444632

• In-home cancer treatment with remote specialist support for patients in the Florida Panhandle

  This program will try giving standard cancer treatments at home to people living in the Florida Panhandle and nearby areas to see if they prefer it and have better treatment satisfaction.

  Recruiting Phase 2 Mayo Clinic · Jacksonville, Florida · NCT07285044

• Genetic markers linked to chemotherapy-related ovarian damage in women who preserved ovarian tissue before treatment

  This project will test whether genetic changes found in frozen ovarian tissue can predict which women aged 18–38 with breast cancer or Hodgkin lymphoma will develop premature ovarian insufficiency after chemotherapy.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, Bologna · NCT07270679

• PET-Guided Dose Reduction for Involved-Site Radiotherapy in Early Unfavourable Hodgkin Lymphoma

  This trial tests whether reducing radiotherapy from 30 Gy to 20 Gy is safe for adults with early unfavourable Hodgkin lymphoma who achieve a metabolic complete response after two ABVD cycles.

  Recruiting Phase 3 Fondazione Italiana Linfomi - ETS · Alessandria and 37 other locations · NCT07256158

• Nivolumab with AVD versus PET-adapted BEACOPP-like for advanced classical Hodgkin lymphoma

  This trial will test whether starting treatment with low-dose nivolumab plus AVD works better than a PET-adapted BEACOPP-like approach for adults (18–60) with advanced classical Hodgkin lymphoma.

  Recruiting at 3 sites Phase 2 St. Petersburg State Pavlov Medical University · Moscow and 2 other locations · NCT07234487

• 12-week high-intensity interval training for recent survivors of childhood and young-adult Hodgkin lymphoma

  This test tries a 12-week, remotely supervised high-intensity interval training (HIIT) program to see if recently treated survivors of childhood, adolescent, and young adult Hodgkin lymphoma can complete the program and improve fitness and health markers.

  Recruiting St. Jude Children's Research Hospital · Memphis, Tennessee · NCT07222345

• PET-guided first-line nivolumab plus chemotherapy for advanced Hodgkin lymphoma

  This pilot trial tests whether adding nivolumab to initial chemotherapy and changing treatment based on an early PET scan helps adults with advanced classical Hodgkin lymphoma.

  Recruiting Phase 2 National Research Center for Hematology, Russia · Moscow · NCT07209059

• Mozobil (plerixafor) to mobilize stem cells for autologous transplant

  This trial will test whether starting with G‑CSF and giving Plerixafor only when needed can collect enough stem cells for adults with multiple myeloma or lymphoma undergoing autologous transplant while possibly lowering engraftment syndrome.

  Recruiting Phase 2 Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07188090

• CMV Triplex vaccine to boost immunity and prevent CMV after haploidentical stem cell transplant

  This trial tests whether giving a CMV-MVA Triplex vaccine to donors and/or recipients, with or without the antiviral letermovir, can boost CMV immunity and prevent CMV viremia in people having haploidentical stem cell transplants.

  Recruiting at 3 sites Phase 1 City of Hope Medical Center · Duarte, California and 2 other locations · NCT07020533

• BrECADD for stage 2B–III classical Hodgkin lymphoma

  This tests the BrECADD chemotherapy combination in adults 18–60 with stage 2B (with risk factors) or stage III classical Hodgkin lymphoma and uses ctDNA to help track treatment response.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT07002216

• Carmustine treatment for lymphoma patients

  This study is testing if adding a new drug called VI-0609 to a standard treatment helps lymphoma patients do better after a stem cell transplant.

  Recruiting at 4 sites Phase 2 Vivus LLC · Goodyear, Arizona and 3 other locations · NCT06915246

• Proton therapy for Hodgkin Lymphoma patients

  This study is testing if proton therapy is a safer and effective treatment for early-stage Hodgkin Lymphoma patients who have already had chemotherapy.

  Recruiting at 6 sites Uppsala University Hospital · Gothenburg and 5 other locations · NCT06883604

• Combining brentuximab vedotin with standard chemotherapy for Hodgkin lymphoma in adults

  This study is testing if adding a new drug called brentuximab vedotin to standard chemotherapy can help adults with untreated Hodgkin lymphoma feel better and improve their treatment results.

  Recruiting at 5 sites Phase 4 Takeda · Vijayawada, Andhra Pradesh and 10 other locations · NCT06831370

• Using PD-1 inhibitors to prevent relapse in Hodgkin lymphoma after stem cell transplant

  This study tests whether PD-1 inhibitors can help prevent relapse in young adults with Hodgkin lymphoma after they’ve had a stem cell transplant.

  Recruiting at 4 sites Phase 2 St. Petersburg State Pavlov Medical University · Astana and 3 other locations · NCT06812858

• Exploring immune responses in Hodgkin's lymphoma patients treated with pembrolizumab

  This study is trying to see how the immune system of patients with relapsed Hodgkin's lymphoma responds to the treatment pembrolizumab to help improve future therapies.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna · NCT06733987

• Using Riluzole to Help Breast Cancer Survivors with Cognitive Issues

  This study is testing if the medication riluzole can help breast cancer survivors who are having trouble with thinking and memory feel better.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT06580002

• Assessing lymphoma treatment response using advanced DNA analysis

  This study is testing if analyzing DNA from blood can help doctors see how well treatment is working for patients with aggressive B-cell lymphoma without using radiation from scans.

  Recruiting National Taiwan University Hospital · Taipei · NCT06550427

• Using Darzalex Faspro to lower antibody levels before stem cell transplant

  This study is testing if a new treatment called Darzalex Faspro can help lower harmful antibodies in adults so they can safely receive a stem cell transplant for blood cancers.

  Recruiting Early Phase 1 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT06398457

• Using Wisconsin ginseng to reduce cancer-related fatigue

  This study is testing if Wisconsin ginseng can help reduce fatigue in cancer patients compared to a placebo over eight weeks.

  Recruiting at 14 sites Phase 3 Mayo Clinic · Albert Lea, Minnesota and 14 other locations · NCT06395441

• Change in how kids and young adults with Hodgkin or non-Hodgkin lymphoma process medicines

  This study will test whether giving small probe medicines can show changes in how children and young adults (ages 6–25) with Hodgkin or non-Hodgkin lymphoma metabolize drugs during their cancer treatment.

  Recruiting Phase 1 Murdoch Childrens Research Institute · Melbourne, Victoria · NCT06383338

• Treatment for early stage bulky Hodgkin lymphoma

  This study is testing a new treatment that combines a targeted drug with standard chemotherapy to see if it helps people with early stage bulky Hodgkin lymphoma.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Miami, Florida and 7 other locations · NCT06377566

• Using post-transplant cyclophosphamide and ATG for blood cancer transplants

  This study is testing whether using post-transplant cyclophosphamide and ATG can help prevent graft-versus-host disease in patients with blood cancers who are getting stem cell transplants.

  Recruiting Phase 1/2 Instituto Nacional de Cancer, Brazil · Rio de Janeiro, Rio de Janeiro · NCT06299462

• Understanding the causes and outcomes of lymphoma in Chinese patients

  This study looks at the clinical and genetic details of lymphoma patients in China to see how these factors affect the disease and its outcomes.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT06203652

• Banked C7R-modified allogeneic CD30-targeted CAR T cells for CD30-positive lymphomas

  This will try a donated (banked) C7R.CD30.CAR-EBVST cell infusion to treat people aged 12–75 whose CD30-positive lymphoma has returned or not responded to prior treatments.

  Recruiting Phase 1 Baylor College of Medicine · Houston, Texas and 1 other locations · NCT06176690

• Comparing JS004 and Toripalimab to Chemotherapy for Hodgkin Lymphoma

  This study is testing if a new combination of JS004 and Toripalimab can work better than regular chemotherapy for people with Hodgkin lymphoma who haven't responded to previous treatments.

  Recruiting Phase 3 Shanghai Junshi Bioscience Co., Ltd. · Beijing, Beijing Municipality · NCT06170489

• Testing CTX-8371 in patients with advanced cancers

  This study is testing a new treatment called CTX-8371 in patients with advanced cancers to see if it can help them when other treatments haven't worked.

  Recruiting at 11 sites Phase 1 Compass Therapeutics · Birmingham, Alabama and 11 other locations · NCT06150664

• Evaluating AZD3470 for relapsed or refractory blood cancers

  This study is testing a new drug called AZD3470 to see if it can help people with hard-to-treat blood cancers feel better and respond to treatment.

  Recruiting at 28 sites Phase 1/2 AstraZeneca · Duarte, California and 37 other locations · NCT06137144

• Study of crushed venetoclax tablets dissolved in liquid for pediatric patients

  This study tests if crushing venetoclax tablets and mixing them with liquid helps children with blood cancers absorb the medication better and stay safe while taking it.

  Recruiting at 5 sites Children's Hospital Medical Center, Cincinnati · Aurora, Colorado and 5 other locations · NCT06131801

• New cellular therapy for Hodgkin Lymphoma

  This study is testing a new type of cell therapy for people with relapsed or hard-to-treat Hodgkin Lymphoma to see if it is safe and effective.

  Recruiting Phase 1/2 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT06090864

• Vaccination to prevent CMV infection in stem cell transplant patients

  This study is testing a new vaccine to see if it can help prevent CMV infections in patients receiving stem cell transplants from related donors.

  Recruiting at 3 sites Phase 2 City of Hope Medical Center · Duarte, California and 2 other locations · NCT06059391

• Using Tislelizumab for Patients with Hodgkin Lymphoma Who Can't Have Standard Chemotherapy

  This study is testing if a new treatment called tislelizumab can help older patients with Hodgkin lymphoma who can't take standard chemotherapy feel better and manage their disease safely.

  Recruiting at 10 sites Phase 2 Fondazione Italiana Linfomi - ETS · Alessandria, IT and 11 other locations · NCT05977673

• Investigating cognitive impairment in young cancer patients during and after chemotherapy

  This study is testing how chemotherapy affects memory and attention in children and young adults with cancer to better understand their cognitive challenges during and after treatment.

  Recruiting Copenhagen University Hospital, Rigshospitalet · Copenhagen · NCT05840575

• Improving health for lymphoma survivors through diet and exercise

  This study tests if following a Mediterranean diet and doing home exercises can help lymphoma patients on chemotherapy finish their treatment and feel better during it.

  Recruiting University of Miami · Miami, Florida · NCT05839210

• Evaluating MT-601 for patients with relapsed or refractory lymphoma

  This study is testing a new treatment called MT-601 to see if it can help people with relapsed or hard-to-treat lymphoma feel better.

  Recruiting at 7 sites Phase 1 Marker Therapeutics, Inc. · Duarte, California and 6 other locations · NCT05798897

• Combination treatment for relapsed B-cell lymphoma

  This study is testing a new combination of treatments for people with relapsed B-cell lymphoma to see if it helps them respond better and live longer.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT05615636

• New treatment approach for relapsed or refractory Hodgkin lymphoma

  This study is testing a new treatment for people with relapsed or hard-to-treat Hodgkin lymphoma to see if combining certain therapies can help them live longer and feel better.

  Recruiting Phase 2/3 Hospital Regional de Alta Especialidad del Bajio · León, Guanajuato · NCT05595447

• Survey of Brentuximab Vedotin for treating pediatric Hodgkin Lymphoma

  This study looks at how well Brentuximab Vedotin works with standard treatment for kids with Hodgkin lymphoma and checks for any side effects they might have.

  Recruiting Takeda · Tokyo, Tokyo · NCT05481437

• Using Tagraxofusp to treat pediatric patients with relapsed or refractory blood cancers

  This study is testing a new drug called Tagraxofusp to see if it can help children and young adults with tough-to-treat blood cancers feel better and improve their chances of recovery.

  Recruiting at 15 sites Phase 1 Therapeutic Advances in Childhood Leukemia Consortium · Los Angeles, California and 30 other locations · NCT05476770

• Combining targeted immunotherapy with chemotherapy for pediatric lymphoma

  This study is testing if adding a new type of immunotherapy to lower doses of chemotherapy can help children and young adults with certain types of lymphoma while keeping them safe.

  Recruiting at 2 sites Phase 2 New York Medical College · Birmingham, Alabama and 2 other locations · NCT05253495

• Comparing new drugs to standard treatment for relapsed Hodgkin lymphoma

  This study is testing if new drugs Pembrolizumab and Brentuximab vedotin work better than standard treatment for people with relapsed Hodgkin lymphoma.

  Recruiting at 18 sites Phase 2 Canadian Cancer Trials Group · Concord, New South Wales and 17 other locations · NCT05180097

• Evaluating Brentuximab Vedotin for Adults with Hodgkin's Lymphoma

  This study is testing how well Brentuximab Vedotin works and how safe it is for adults with Hodgkin's Lymphoma who are getting or preparing for a stem cell transplant.

  Recruiting at 13 sites Takeda · Wroclaw, Dolnoslskie and 12 other locations · NCT05100056

• Using engineered immune cells with chemotherapy to treat blood cancers

  This study is testing if using special immune cells along with chemotherapy can help people with tough-to-treat blood cancers like B-cell lymphoma and leukemia feel better.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT05092451

• Investigating early ageing in young cancer patients during treatment

  This study is trying to see how cancer treatment affects early aging and heart health in young adults aged 18-39 who are undergoing therapy for cancer.

  Recruiting University Medical Center Groningen · Groningen · NCT05062707

• Reduced-intensity conditioning to lower treatment-related mortality in stem cell transplant patients

  This study is testing a new way to prepare patients for a stem cell transplant to see if it can lower the risk of serious treatment-related complications.

  Recruiting Phase 2 Thomas Jefferson University · Philadephia, Pennsylvania · NCT05031897

• Fecal Microbiota Transplantation to Prevent Complications After Stem Cell Transplantation

  This study is testing whether giving a special stool treatment can help prevent complications like Graft-versus-Host Disease in patients receiving stem cell transplants for blood cancers.

  Recruiting at 3 sites Phase 2 University Hospital, Clermont-Ferrand · Amiens and 19 other locations · NCT04935684

• Comparing T Cell Depletion Methods for Blood Cancer Treatment

  This study is testing different ways to prevent complications after a stem cell transplant for blood cancer to see which method helps patients stay healthy and cancer-free longer.

  Recruiting at 17 sites Phase 2 University of Birmingham · Cardiff, Wales and 16 other locations · NCT04888741

• Brentuximab vedotin for early stage Hodgkin lymphoma treatment

  This study is testing if adding a new drug called brentuximab vedotin to standard chemotherapy can help people with early-stage Hodgkin lymphoma do better in their treatment.

  Recruiting at 72 sites Phase 3 University College, London · Stanford, California and 71 other locations · NCT04685616

• Using stem cell transplant and Polatuzumab Vedotin for treating B-cell lymphomas

  This study is testing if a stem cell transplant followed by a new drug called Polatuzumab Vedotin can help people with different types of B-cell lymphomas feel better.

  Recruiting Phase 1/2 New York Medical College · Valhalla, New York · NCT04491370

• Donor stem cell transplant with chemotherapy and radiation for blood cancers

  This study is testing if a donor stem cell transplant combined with different doses of chemotherapy and radiation can help people with blood cancers recover better.

  Recruiting Phase 2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT04195633

• Stem cell transplantation for blood disorders using specific cell depletion techniques

  This study is testing a new way of using stem cell transplants for children and young adults with blood disorders to see if removing certain cells helps them recover better and improve their quality of life.

  Recruiting Phase 2 New York Medical College · Valhalla, New York · NCT04099966

• Comparing two conditioning regimens for allogeneic hematopoietic cell transplantation

  This study is testing two different treatment plans for patients with blood cancers who are getting stem cell transplants from matched donors to see which one helps them stay healthy longer.

  Recruiting at 10 sites Phase 2 University of Liege · Antwerp and 9 other locations · NCT03852407

• Combining nivolumab and ruxolitinib for treating relapsed Hodgkin lymphoma

  This study is testing if combining two drugs, nivolumab and ruxolitinib, can safely help people with relapsed Hodgkin lymphoma feel better.

  Recruiting at 3 sites Phase 1/2 Big Ten Cancer Research Consortium · Chicago, Illinois and 5 other locations · NCT03681561

• Testing pembrolizumab with GVD for relapsed Hodgkin lymphoma

  This study is testing if combining the immunotherapy drug pembrolizumab with GVD can help people with relapsed Hodgkin lymphoma feel better after their previous treatments.

  Recruiting at 10 sites Phase 2 Memorial Sloan Kettering Cancer Center · Duarte, California and 9 other locations · NCT03618550

• Registry for patients with lymphoid cancers

  This study is collecting information from patients with Hodgkin lymphoma, non-Hodgkin lymphoma, and myeloma to better understand their conditions and improve treatment options.

  Recruiting A.O. Ospedale Papa Giovanni XXIII · Bergamo · NCT03131531

• Auto stem cell transplant for lymphoma patients

  This study tests if a stem cell transplant after chemotherapy can help people with Hodgkin and non-Hodgkin lymphomas, including those with HIV, who are in remission.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT03125642

• Investigating genetic factors in childhood cancer

  This study is trying to find out if certain genes passed down in families can increase the risk of childhood cancer by looking at samples from kids who have had cancer and their relatives.

  Recruiting St. Jude Children's Research Hospital · Memphis, Tennessee · NCT03050268

• Transplantation with modified stem cells and Zoledronate for pediatric cancers

  This study is testing a new way to use modified stem cells and a drug called Zoledronate to see if it can safely help children with tough-to-treat cancers.

  Recruiting Phase 1 University of Wisconsin, Madison · Madison, Wisconsin · NCT02508038

• Access and distribution of unlicensed cryopreserved cord blood units

  This study is testing how well unlicensed frozen cord blood units work for helping both kids and adults with blood cancers recover after a transplant.

  Recruiting at 113 sites Center for International Blood and Marrow Transplant Research · Birmingham, Alabama and 141 other locations · NCT01351545

NIH-funded research (31)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Understanding why Black and Hispanic Hodgkin lymphoma patients have worse survival

  A patient-centered study to uncover social and care factors that contribute to lower survival among Black and Hispanic people with Hodgkin lymphoma across all ages.

  NIH research University of Miami School of Medicine · Coral Gables, United States · NIH-11572148

• Novel combination therapy for non-Hodgkin lymphoma in people and dogs

  A new treatment combo using an oncolytic virus and other therapies is being tested to help people with hard-to-treat non-Hodgkin lymphoma, with studies also involving dogs to better understand responses.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11473229

• Trajectories of Neurotoxicity in young Hodgkin lymphoma patients

  Aging Hodgkin lymphoma patients who are adolescents or young adults may face long-lasting brain and nerve-related side effects from their cancer treatment, and this study aims to map how those problems develop over time.

  NIH research University of Rochester · Rochester, United States · NIH-11432883

• Combination therapy approach for non-Hodgkin lymphoma (NHL)

  A Mayo Clinic team is testing a new combination treatment for non-Hodgkin lymphoma to improve responses in patients and in dogs with similar disease.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11402652

• Multi-antigen T cell therapy for relapsed NHL

  A patient-derived T cell therapy called MT-601 targets six tumor-associated antigens to help treat relapsed non-Hodgkin lymphoma after other therapies may have failed.

  NIH research Marker Therapeutics, INC. · Houston, United States · NIH-11374461

• Personalized de‑intensification of therapy for NLP Hodgkin lymphoma

  A clinician-scientist at Stanford is developing a patient-centered program to tailor and reduce therapy for nodular lymphocyte-predominant Hodgkin lymphoma using tumor and blood samples.

  NIH research Stanford University · Stanford, United States · NIH-11355615

• Combining international Hodgkin lymphoma data to understand long-term treatment effects

  This project brings together trial and registry data to learn how treatments affect long-term health in adults with Hodgkin lymphoma.

  NIH research Tufts Medical Center · Boston, United States · NIH-11285423

• Precision targeted radioactive antibody therapy for non-Hodgkin lymphoma

  Researchers are developing more precise radioactive antibodies to treat people with CD20-positive non-Hodgkin lymphoma.

  NIH research Washington University · Saint Louis, United States · NIH-11241103

• AI-designed drugs targeting a common lymphoma mutation (MYD88 L265P)

  Researchers are using artificial intelligence to create and test new drugs that block a common MYD88 mutation found in many B‑cell non‑Hodgkin lymphomas to help people with these cancers.

  NIH research Baylor College of Medicine · Houston, United States · NIH-11235842

• New combination therapy for non-Hodgkin lymphoma

  A virus-based combination treatment aims to boost the immune system to help people and companion dogs with relapsed or treatment-resistant diffuse large B-cell lymphoma.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11211672

• New combination treatment for diffuse large B‑cell lymphoma

  This project is trying a virus-based therapy together with checkpoint immunotherapy for people (and companion dogs) with relapsed diffuse large B‑cell lymphoma.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11180362

• MT-601 T Cell Therapy for Relapsed Non-Hodgkin Lymphoma

  This opportunity explores a new T cell therapy called MT-601 for people with Non-Hodgkin Lymphoma that has returned after previous treatments.

  NIH research Marker Therapeutics, INC. · Houston, United States · NIH-11164733

• New antibody treatment for Non-Hodgkin Lymphoma and a type of skin lymphoma

  This project is testing a new antibody treatment, called BITR2101, for people with certain types of cancer, including Non-Hodgkin Lymphoma and Cutaneous T Cell Lymphoma.

  NIH research Boston Immune Technologies and Therapeutics, INC. · Winchester, United States · NIH-11131238

• Understanding how Hodgkin lymphoma cells evade the immune system

  This study is looking at how Hodgkin lymphoma cells manage to hide from the immune system and keep growing, focusing on a specific protein complex, and it aims to find new ways to improve treatments for patients dealing with advanced or returning cases of this cancer.

  NIH research Research Inst of Fox Chase Can Ctr · Philadelphia, United States · NIH-11097159

• New targeted treatments for non-Hodgkin lymphoma

  This study is working on new treatments for non-Hodgkin lymphoma using advanced antibodies that could be more effective and safer, with the hope of offering better options for patients like you.

  NIH research Washington University · Saint Louis, United States · NIH-11050386

• Understanding genetic factors that affect treatment success in Hodgkin lymphoma

  This study is looking at how certain genetic changes and bits of tumor DNA in your blood can help doctors figure out the best treatment for people with classical Hodgkin lymphoma, aiming to create personalized plans that reduce the side effects of chemotherapy.

  NIH research Stanford University · Stanford, United States · NIH-11047713

• Understanding the long-term effects of treatment in Hodgkin lymphoma patients

  This study is looking at how treatments for Hodgkin lymphoma might affect your health in the long run, especially regarding risks for other cancers and heart problems, using information from over 12,000 patients to help understand these effects better.

  NIH research Tufts Medical Center · Boston, United States · NIH-11046511

• Combining therapies to improve treatment for non-Hodgkin lymphoma

  This study is looking at a new treatment for diffuse large B-cell lymphoma, the most common type of non-Hodgkin lymphoma, to find out how to make current therapies work better, and it involves comparing cases in people and dogs to learn more about how to fight this cancer effectively.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11043487

• Understanding why Black and Hispanic patients with Hodgkin lymphoma have lower survival rates

  This study is looking into why Black and Hispanic patients with Hodgkin lymphoma have lower survival rates, and it aims to find out what challenges they face so that we can create better support and treatment options for them.

  NIH research University of Florida · Gainesville, United States · NIH-11030387

• Investigating heart and brain function in survivors of Hodgkin Lymphoma

  This study is looking at how treatments for Hodgkin Lymphoma might impact heart and lung health, and how that could affect brain function in survivors, so if you're a survivor, we’d love for you to join us to help understand these connections better!

  NIH research St. Jude Children's Research Hospital · Memphis, United States · NIH-11009048

• Targeting a key driver of Non-Hodgkin Lymphoma using artificial intelligence

  This study is using smart computer technology to find new ways to create medicines that can help people with Non-Hodgkin Lymphoma by targeting specific proteins that are hard to treat, especially those linked to a common gene mutation.

  NIH research Baylor College of Medicine · Houston, United States · NIH-10985003

• Investigating how HIV affects the development of classic Hodgkin lymphoma

  This study is looking at why people with HIV might have a higher chance of developing classic Hodgkin lymphoma, and it aims to understand the differences in their immune system and genes that could lead to this cancer, with the help of patient samples.

  NIH research Fred Hutchinson Cancer Center · Seattle, United States · NIH-10954155

• Personalized treatment approaches for a rare type of Hodgkin lymphoma

  This study is looking to create personalized treatment plans for people with nodular lymphocyte-predominant Hodgkin lymphoma by examining their tumor and blood samples to find out which therapies might work best for them, helping to reduce side effects while still being effective.

  NIH research Stanford University · Stanford, United States · NIH-10948864

• New T cell therapy for patients with relapsed Non-Hodgkin Lymphoma

  This study is testing a new treatment for people with relapsed Non-Hodgkin Lymphoma that uses their own immune cells to better fight cancer by targeting multiple markers on the cancer cells, with the hope of making the treatment more effective and lowering the risk of the cancer coming back.

  NIH research Marker Therapeutics, INC. · Houston, United States · NIH-10922163

• New combination therapy for non-Hodgkin lymphoma

  This study is looking at a new treatment approach for people with diffuse large B-cell lymphoma (DLBCL), a common type of cancer, to help improve how well therapies work, especially for those with advanced cases, by learning from both human and dog cases.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-10918057

• New treatment targeting cancer cells and their supportive environment in Non-Hodgkin Lymphoma.

  This study is testing a new treatment called BITR2101 that targets a specific part of cancer cells to help stop the growth of Non-Hodgkin Lymphoma, especially for those with Cutaneous T Cell Lymphoma, and it may be used on its own or with other therapies to improve patient outcomes.

  NIH research Boston Immune Technologies and Therapeutics, INC. · Winchester, United States · NIH-10911718

• Investigating the genetics of Hodgkin lymphoma that doesn't respond to treatment

  This study is looking at the genetic changes in Hodgkin lymphoma to find out why some patients don’t respond to standard treatments or have relapses, with the hope of discovering better treatment options for those who need them.

  NIH research Washington University · Saint Louis, United States · NIH-10908251

• Investigating aging-related biomarkers in long-term survivors of Hodgkin lymphoma

  This study is looking at how aging affects brain health in long-term survivors of Hodgkin lymphoma who didn't receive certain brain-targeting treatments, with the hope of finding clues that could help improve their memory and thinking skills.

  NIH research University of Rochester · Rochester, United States · NIH-10876288

• Improving CAR T cell therapy for Hodgkin Lymphoma

  This study is testing a new treatment for people with Hodgkin Lymphoma that uses specially modified immune cells to better find and attack cancer cells, and it's designed for those whose cancer has come back or hasn't responded to other treatments.

  NIH research Univ of North Carolina Chapel Hill · Chapel Hill, United States · NIH-10866397

• Investigating Hodgkin lymphoma in people living with HIV in South Africa

  This study is looking at how Hodgkin lymphoma affects people living with HIV in South Africa, comparing their experiences with those who don’t have HIV, to better understand how factors like organ health and other infections might influence treatment and outcomes.

  NIH research Johns Hopkins University · Baltimore, United States · NIH-10825552

• Finding ways to identify when non-Hodgkin lymphoma comes back using electronic health records.

  This study is working on new ways to use health records to better spot when non-Hodgkin lymphoma comes back, especially for those with diffuse large B-cell lymphoma or follicular lymphoma, so that patients can get better care and monitoring.

  NIH research Univ of Massachusetts Med Sch Worcester · Worcester, United States · NIH-10424952

Related topics

Quick answers

How many Hodgkin Lymphoma clinical trials are recruiting right now?

64, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 27 countries. The most sites are in United States (38 trials), Italy (6 trials), Australia (5 trials), China (4 trials), Russia (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 24, Phase 1: 10, Phase 1/2: 6, Phase 3: 4. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →